Affiliations: [a] Department of Urology, King George's Medical University, Lucknow, India | [b] Centre of Biomedical Research, SGPGIMS Campus, Lucknow, India
Correspondence:
[*]
Corresponding author: Navneeta Bansal, Department of Urology, King George's Medical University, Chowk, Lucknow, 226003 UP, India. Tel.: +91 522 6570321; Fax: +91 522 2256543; E-mail: navneeta23@gmail.com
Abstract: Urinary bladder cancer (BC) is fifth most common cancer worldwide; the
diagnostic methods are mostly instrumental approaches including cystoscopy
and cytology. Since BC recurrence rate is high, consequently requires
long-term follow-up. The molecular assays that can precisely identify BC at
an early stage are obligatory. Although several noninvasive urine and blood
samples based biomarkers have been proposed in the last decade but only few
have been approved by Food and drug administration (FDA) for clinical
purpose. Hence the search for more suitable biomarker is still on. In this
review, we summarize the urine and blood based metabolic and protein tests
not only for determination but also BC patient surveillance.
Keywords: Bladder cancer, metabolomics, proteomics, FDA
